The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | The future of HER2-directed therapies in non-small cell lung cancer
Joshua Sabari, MD, New York University Langone Health, New York, NY, provides an overview of the growing options in the HER2 space for non-small cell lung cancer (NSCLC). Zongertinib stands out due to its clean side effect profile, with minimal toxicity, no risk of interstitial lung disease, and no significant gastrointestinal or dermatological side effects. The approval of trastuzumab deruxtecan will also provide patients with much needed options. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The HER2 space is an exciting space that we have multiple options shortly becoming available. So zongertinib will likely be approved in the second line setting in the United States. We just recently saw data from BAY 292 and we have an approval for T-DXd, an accelerated approval in the second line setting and HER2 being an ADC targeting HER2. So with multiple options, I think it’s critical to talk to patients about what the side effect profiles are...
The HER2 space is an exciting space that we have multiple options shortly becoming available. So zongertinib will likely be approved in the second line setting in the United States. We just recently saw data from BAY 292 and we have an approval for T-DXd, an accelerated approval in the second line setting and HER2 being an ADC targeting HER2. So with multiple options, I think it’s critical to talk to patients about what the side effect profiles are. zongertinib really differentiates itself in that it is clean, it has very little toxicity for patients, no risk of interstitial lung disease, we don’t really see many significant AST and ALT elevation or abnormalities, and most importantly to me, no real diarrhea and no real significant rash. So these patient reported outcomes are going to be critical in differentiating the different therapeutic options for patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consulting or Advisory Role – Abbvie; AstraZeneca; Genentech/Roche; Janssen; Janssen (Inst); Loxo/Lilly; Loxo/Lilly (Inst); Medscape; Mirati Therapeutics; Mirati Therapeutics (Inst); Pfizer; Regeneron; Regeneron (Inst); Sanofi; Takeda
